Loading...
Protalix Q1 2025 Earnings Report
Protalix BioTherapeutics reported its first quarter 2025 financial and business results, showing increased revenues and progress in clinical trials.
Key Takeaways
Protalix BioTherapeutics reported a solid first quarter in 2025 with a significant increase in revenues from selling goods. The company is focused on advancing its gout candidate, PRX-115, into a phase II clinical trial later this year, following promising phase I results.
Total revenue for Q1 2025 was $10.113 million, an increase from $3.748 million in Q1 2024.
Net loss for Q1 2025 was $3.619 million, or $0.05 per share, an improvement from a net loss of $4.595 million, or $0.06 per share, in Q1 2024.
The company successfully completed the First-in-Human (FIH) phase I clinical trial of PRX-115, its gout candidate, in 2024.
Protalix plans to initiate a phase II clinical trial for PRX-115 in patients with gout during the second half of 2025.
Protalix
Protalix
Protalix Revenue by Segment
Protalix Revenue by Geographic Location
Revenue by Segment
Selling Goods Revenue
CapyFin.comLicense and R&D Services Revenue
CapyFin.comRevenue by Geographic Location
Pfizer Revenue
CapyFin.comFiocruz (Brazil) Revenue
CapyFin.com Forward Guidance
Protalix BioTherapeutics is focused on advancing its lead gout candidate, PRX-115, into a Phase II clinical trial in the second half of 2025, building on promising Phase I results. The company also continues to evaluate other pipeline candidates for future development.
Positive Outlook
- Successful completion of the First-in-Human (FIH) phase I clinical trial of PRX-115.
- Preliminary results of PRX-115 FIH study demonstrate potential for effective uric acid-lowering treatment with wide dosing interval.
- Plans to initiate a phase II clinical trial for PRX-115 in patients with gout during the second half of 2025.
- Continued evaluation of additional pipeline candidates, including PRX-119 and early-stage clinical assets.
- PRX-115 results were presented at the American College of Rheumatology (ACR) Convergence 2024, indicating positive scientific recognition.
Challenges Ahead
- Further studies are needed to confirm the long-term safety and efficacy of PRX-115.
- Expectation of minimal revenues from license and R&D services other than potential regulatory milestone payments.
- Drug discovery and development involve a high degree of risk, and final clinical trial results may differ from preliminary findings.
- Risks related to the commercialization of Elfabrio®, including market acceptance, competition, reimbursement, and regulatory actions.
- Potential disruptions to operations due to geopolitical conflicts and instability in the banking industry.